Topic Archives: Amgen (AMGN)

What set me off on this rant was the very first comment on the piece that posted on January 31st, “Looking Backward – And a Peek in the Other Direction.”   Here’s the comment: “Thanks, Doc. Hope you will comment on the news out of Israel this week:” Naturally, I looked, and what I found […]

When I last took a look at what was happening in the treatment of migraines, I took careful pains to elucidate the differences between migraines and a plain old bad headache – the fact that migraines affect only one side of the head, and a detailed disquisition on the symptoms that many migraineurs (that’s the […]

We’ve seen a long stream of earnings reports and other worthwhile bits of data on Real Money Portfolio stocks since I last wrote to you, including some that actually included some interesting news, so prepare for a lot of quick updates…. Medical Properties Trust (MPW) reported another quarter of ho-hum… pretty much met the forecasts, […]

[ed note: Michael Jorrin, who I like call “Doc Gumshoe,” is a longtime medical writer who shares his thoughts with us a couple times a month — his articles are non-financial in nature, his words and opinions are his own, and you can see his bio and his past pieces here. Enjoy!] Indulge me while […]

[ed note: Michael Jorrin, who I like to call “Doc Gumshoe”, is a longtime medical writer (not a doctor) who shares his thoughts with us from time to time, generally on non-financial topics in health and medicine (as today, though, he mentions a couple publicly traded companies). His words and opinions are his own.] The […]

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. His words and opinions are his own, and he has agreed to our trading restrictions.] Want to see something really cool? A hot video clip from a steamy biotech thriller? Watch this. Better yet, when you pull up the video viewing frame, […]

[Ed. Note: Dr. KSS writes about medical topics and biotech stocks for the Irregulars. He has agreed to our trading restrictions, and his thoughts and words are his own. Enjoy!] Any discussion of cholesterol immediately turns Brobdingnagian, such are the extremes in question. Statins, which lower LDL cholesterol, are bombastically the best-selling drugs of all […]

Today we’re sharing another piece from our medical contributor, “Doc Gumshoe” — we have added the stock tickers to the companies he mentions for your researching convenience, but this survey of the state of cancer research — which will hopefully be good background help to folks trying to understand the basic science behind pitches for […]


  • Avatar

    $RDUS Long Radius rises after safety of Amgen osteoporosis drug questioned Shares of Radius Health (RDUS) are tradi...

  • Avatar

    $ABBV $GILD $AMGN - An interesting article from IBD evaluating comparatively three biotech giants "AbbVie Stronger B...

  • Avatar

    Pre-market actions, 1/6, per IBD at 8:45am In Motion: Amgen, Regeneron, Ionis, Verizon Premarket action was a mixe...


    Out at Amgen ($AMGN). Biotech buoyancy doing nothing for shares. Out for slight profit....

  • LongOnLife

    We don't discuss Amgen $AMGN much on this site but I follow them. Here's news of another rejection from the FDA. http://...


    I put a little Amgen $AMGN in my portfolio today as a trading buy. Earnings have awakened the street to what a powerhous...

  • Avatar

    $CLCD long. Amgen ($AMGN) and Novartis’ ($NVS) migraine drug erenumab has hit the primary endpoint in a Phase II trial...

  • Avatar

    Amgen (AMGN) looking mighty fine on cancer front.

  • Avatar

    Interesting Baron's article. Gilead Science, How bad can it get? Email Print smaller Larger By Ben Levisohn ...

  • Michael Jorrin (aka Doc Gumshoe)

    Not to blow my own horn too blatantly, but here's what I said about Kite in a Doc Gumshoe posting back in February. I ...

  • SoGiAm

    Don’t Buy Gilead’s Headline Gilead Sciences (GILD – NASDAQ) By Bottarelli Research Published Friday, May 01, 20...

  • We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.

    More Info